Narcotic analgesics cause addiction by poorly understood mechanisms, involving µ opioid receptors (MOR). Previous cell culture studies have demonstrated significant basal, spontaneous MOR signaling activity, but its relevance to narcotic addiction remained unclear. In this study, we tested basal MORsignaling activity in brain tissue from untreated and morphine pretreated mice, in comparison to antagonists-induced withdrawal in morphine-dependent mice. Using 35 S-GTPγS binding and adenylyl cyclase activity assay in brain homogenates, we demonstrated that morphine pretreatment of mice enhanced basal MOR signaling in mouse brain homogenates, and moreover, caused persistent changes in the effects of naloxone and naltrexone -antagonists that elicit severe withdrawal in dependent subjects.
JPET # 54049 5 chronic agonist treatment converts neutral antagonists into inverse agonists at δ opioid receptors in cell culture (Liu and Prather, 2002) . Changes in ligand properties from neutral antagonist to inverse agonist effects also occur at other G protein coupled receptors. Prior stimulation at the β 2 -adrenergic receptor, for example, has been shown to enhance the inverse agonist activity of certain antagonists (Chidiac et al., 1994) . Furthermore, regulation of basal signaling of the bradykinin B2 receptor determines the efficacy of a ligand as either partial agonist or inverse agonist (Fathy et al., 1999) . Similarly, protean agonism at histamine H3 receptors has been reported in vitro and in vivo, indicating that a ligand can have agonist, neutral antagonist, or inverse agonist at the same receptor type, depending on the cell context (Gbahou et al., 2003) . Therefore, the intrinsic efficacy of a ligand -previously thought of as an independent property -appears to depend upon the context of tissue and cellular environment (Fathy et al., 1999; Kenakin, 2002) . The relevance of these results to opioid pharmacology in intact animals and human subjects remained unclear.
In morphine-dependent subjects, naloxone and naltrexone potently elicit severe withdrawal whereas the effects on drug-naïve subjects are minimal (Martin and Eades, 1977; Heishman et al., 1990; Baldwin and Koob, 1993; June et al., 1995; Parker and Joshi, 1998) . Antagonist effects are not readily accounted for by simply blocking morphine at MOR (Wang et al., 1994) . This suggested the hypothesis that naloxone and naltrexone precipitate withdrawal by suppressing basal MOR signaling in JPET # 54049 8 hour. To test inverse agonist effects, we used 4 mM MgCl 2 and 10 µM GDP in the assay buffer, and reactions were incubated at 30°C for 30 min.
Adenylyl cyclase activity: Brain tissues were homogenized in ice cold buffer (40 ml for 100 mg tissue) containing 20 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.5 mM DTT, 1 mM MgCl 2 , 250 mM sucrose, and 0.5 mM phenylmethyl sulfonyl fluoride (PMSF), then centrifuged at 27,000 × g for 15 min. The pellets were washed once with the same buffer. Pellets from the second centrifugation were resuspended in the same buffer at a protein concentration of ~10 mg/ml. Adenylyl cyclase activity was analyzed in assay buffer containing 50 mM Tris-HCl, pH 7.6, 5 mM MgCl 2 , 250 µM ATP, 5 mM creatine phosphate, 250 µg/ml creatine kinase, 100 µg membrane protein, and 1 µM test drugs in a total volume of 60 µl. The reaction mixture was incubated at 37°C for 10 min, and then stopped by boiling for 2 min. The levels of cAMP in the supernatant were determined by using a 3 H-cAMP assay kit (Amersham).
Naltrexone induced withdrawal jumping:
Mice were pretreated with morphine over 3 days as described above (Wang et al., 2001b ) (Bilsky et al., 1996) . Naltrexone (0.1 mg/kg) and 6β-naltroxol (1 mg/kg) (equipotent doses with respect to antagonism of morphine analgesia (Wang et al., 2001b) ) were injected i.p at different times (4, 8, 12, 24, 48 and 72 hours) after the last morphine dose. Several experiments were also performed with 1 mg/kg naltrexone and 10 mg/kg 6β-naltroxol at 8 and 48 hours after the last morphine dose. Mice were videotaped for 20 min after antagonist injection. A trained observer who was blinded to experimental treatments reviewed the videotapes. JPET # 54049 9 individually placed into the chambers and allowed to habituate for 30 min. After 30 min, morphine was injected at a dose of 30 mg/kg (s.c.), and the mice were immediately placed back into the chambers for an additional 30 minutes of monitoring. Naltrexone (1.0 mg/kg), 6β-naltrexol (10 mg/kg) or saline injections were then administered i.p., and mice were monitored for an additional 60 min. Measurement of x-y position was taken every 100 ms, and total distance traveled in one-minute intervals (bins) was calculated.
Mass spectrometric analysis of naltrexone and 6β-naltrexol in mouse brain homogenates: Mice were injected i.p with either 1.0 mg/kg naltrexone, or 1.0 or 10 mg/kg 6β-naltrexol, and sacrificed after 10 min.
Blood samples and brains were collected. Whole brain was excised and homogenized in a 1:3 volume (g/ml)
phosphate buffered saline solution (pH 7.3), and the homogenate stored at -70 o C. 50µl mouse brain homogenate was extracted with methyl-t-butyl ether. Each sample was analyzed for naltrexone and 6β-naltrexol using mass spectrometry, with a LC/MS/MS PE-Sciex API 3000 system equipped with a BDS C18
Column ( homogenates from MOR-deficient mice ( Figure 1C ), confirming that the increase in 35 S-GTP-γ-S binding is due to MOR activation. Upon pretreatment with a single dose of morphine, the dose-response curve (measured 4.5 hours after morphine injection) shifted to the right, with EC 50 values increasing to 2.9 ± 0.5 µM (morphine) and 400 ± 27 nM (DAMGO) respectively (n=3, p<0.05, t-test). This indicates partial desensitization of MOR to subsequent agonist stimulation. This commonly observed phenomenon is thought to contribute to narcotic tolerance. However, the shift after a single dose of morphine was rather modest and did not further increase substantially with 3-day multiple dosing ( Figure 1A and 1B). The EC 50 values for morphine and DAMGO in brain homogenates from mice after 3-day morphine pretreatment were 3.2 ± 0.7 µM and 523 ± 77 nM, respectively. As desensitization of MOR coupling to G proteins was relatively limited, this mechanism may account only for a small portion of the pronounced antinociceptive tolerance to morphine in vivo.
To test for basal MOR activity in brain homogenates, we took advantage of the full inverse agonists β-CNA and BNTX, shown to suppress basal MOR activity in tissue culture (Wang et al., 2000; Wang et al., 2001b We next tested the effects of naloxone and naltrexone on basal 35 S-GTP-γ-S binding ( Figure   4A and 4B). Both agents showed a small degree of agonist-like activity in brain homogenates from untreated animals -as observed in tissue culture homogenates (Wang et al., 2001b) . In contrast, after morphine pretreatment (3-day multiple doses), these two agents served as inverse agonists, decreasing Importantly, after 3-day multiple-dose morphine pretreatment in the chronic model of narcotic dependence, inverse naloxone effects on basal MOR activity lasted for at least 72 hours ( Figure 5 ). Five days after the last morphine dose, naloxone-induced 35 S-GTP-γ-S binding leveled out at ~+1-2%, which was no longer significantly different from the control value (+4%). The precision of the assay was insufficient to determine whether chronic morphine pretreatment caused a small but even longer lasting change in inverse naloxone effects.
Adenylyl cyclase activity assay in brain homogenates
G protein coupling is the first step in MOR activation, followed by effector regulation.
Specifically, MOR inhibits adenylyl cyclase via inhibitory Gα i/ο subunits. Therefore, inverse agonists are expected to increase adenylyl cyclase activity by removing the inhibition generated from basal MOR activity, as shown in cell culture (Wang et al., 2001b) . Shown in Figure 6A , in striatum membrane homogenates from control mice, the inverse agonists BNTX and β-CNA significantly increased adenylyl cyclase activity, whereas naloxone and naltrexone had no effect. After chronic morphine pretreatment (3-day injections), naloxone and naltrexone increased adenylyl cyclase activity, indicating that they now act as inverse agonists. On the other hand the effects of BNTX and β-CNA did not change, indicating that BNTX and β-CNA are full inverse agonists before morphine treatment in this assay. The effects of naloxone and naltrexone in pretreated samples are comparable to that of BNTX and β-CNA. The inverse agonist effects of naloxone and naltrexone were sustained for at least 24hrs after the last morphine dose. In contrast to naloxone and naltrexone, the neutral antagonist 6β-naltrexol had no effect on adenylyl cyclase activity regardless of morphine pretreatment. These results are consistent with results from and 24 hrs after the last morphine dose.
Antagonist-induced withdrawal jumping
To test whether suppression of basal MOR activity by naloxone (naloxone-induced inverse effects) correlates with the time-course of antagonist-induced withdrawal, we measured withdrawal jumping in morphine-dependent mice (single dose and 3-day morphine pretreatment) using naltrexone and 6β-naltrexol. In mice, vertical jumping is widely considered to be the most sensitive and reliable index of withdrawal intensity and is the most commonly used measure (Way et al., 1969; Saelens et al., 1971; Smits, 1975; Bilsky et al., 1996; Kest et al., 2001) . After a single i.p.dose of 100 mg/kg morphine, naltrexone-induced withdrawal jumping, which was maximal at 4 hours and then ceased between 6-10 hours (data not shown). However, after 3-day multiple doses of morphine pretreatment, naltrexone (0.1 mg/kg)-induced withdrawal jumping was pronounced at 4-8 hours, remained detectable at 48 hours after last morphine dose, and subsided at 72 hours ( Figure 7A ). In contrast, the neutral antagonist 6β-naltrexol -given at equipotent doses (1 mg/kg) for blocking morphine analgesia (Wang et al., 2001b ) -induced significantly fewer jumps than naltrexone at all time points tested ( Figure 7A ).
When naltrexone or 6β-naltrexol were injected at higher doses (1.0 and 10 mg/kg, respectively, at 8, and 48 hrs after morphine dose), 6β-naltrexol precipitated 25 jumps, which was approximately 38% of the withdrawal jumping elicited by naltrexone (66 jumps) at 8 hours ( Figure 7B ). However, no significant withdrawal jumping was observed with 6β-naltrexol at 48 hours after the last morphine dose (comparing to saline injection, p>0.05), while significant jumps were still observed with naltrexone injection (P<0.05) ( Figure 7B ). These results clearly distinguish the pharmacological actions of the inverse agonist naltrexone and the neutral antagonist 6β-naltrexol given at equipotent doses 
Morphine-induced locomotor activity
To rule out the possibility that the difference between naltrexone and 6β-naltrexol in causing withdrawal jumping has arisen from different rates by which these agents enter the central nervous system, we observed the reversal of morphine-induced locomotor activity by naltrexone (1 mg/kg) and 6β-naltrexol (10 mg/kg), given at equipotent doses for antagonism of morphine antinociception (Wang et al., 2001b) . Shown in Figure 8A and 8B, both antagonists rapidly reversed morphine effects at the same rate. This suggests that the influx rate of these two drugs into the brain is comparable at the doses used for precipitating withdrawal jumping.
Plasma and brain levels of naltrexone and 6β-naltrexol
Naltrexone has been reported to metabolize to 6β-naltrexol (Chatterjie et al., 1974; Ferrari et al., 1998 ) -a process that could be reversible in vivo. To ascertain the level of administered drugs and metabolites in the blood and brain after administration of naltrexone and 6β-naltrexol in mice, the compounds were extracted from blood and brain tissue and measured by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS) (Shi, W. Gee, E.T. Protocol for UCSF Drug Studies Units, DSU # 94-A, 2000). Shown in Table 1 , at 10 minutes after a dose of 1.0 mg/kg naltrexone, and an equipotent dose of 10.0 mg/kg 6β-naltrexol, brain levels were 69 ± 20 naltrexone and 89 ± 6 ng/g 6β-naltrexol, respectively (S.D., n=3). Therefore, the concentration of 6β-naltrexol in the brain is comparable to that of naltrexone at 10 min after injection. Neither 6β-naltrexol nor naltrexone was detectable (<1ng/g; <3 nM) as a metabolite of each other. Thus, both naltrexone and 6β-naltrexol exerted their effect in the brain of mice without substantial metabolic interconversion. statistically from that of BNTX and β-CNA, we assume that naloxone and naltrexone did convert into full inverse agonists with respect to adenylyl cyclase activity.
Our results confirm earlier reports on a change in naloxone's and naltrexone's antagonist properties after morphine-pretreatment in cell culture (Wang et al., 1994; Liu and Prather, 2001; Wang et al., 2001b A single dose of morphine has a tendency to enhance the inverse effects of BNTX and β−CNA, while a three-day pretreatment period caused only a marginal further increase ( Figure 2B ). This is supported by the results obtained with naloxone and naltrexone. A single morphine dose is sufficient to change naloxone and naltrexone into inverse agonists (data not shown). This was unexpected if one assumes that the inverse agonsit effect of naloxone and naltrexone are directly related to the severity of antagonist-stimulated withdrawal, which increases with increasing dependence. However, the cAMP system (a key component of dependence) is also markedly upregulated in the dependent state, such that naloxone's effects are amplified yielding a larger cAMP overshoot with increasing dependence. Other signaling pathways may also contribute in the dependent state in accentuating the response to an inverse agonist. Thus, the inverse effects of naloxone and naltrexone provide a sensitive measure of basal MOR activity in the dependent state. Dose-response curves for naloxone and naltrexone in morphine-dependent brain homogenates show that 10-100 nM concentrations are This article has not been copyedited and formatted. The final version may differ from this version. (Gonzalez-Maeso et al., 1999) . Therefore, it is difficult to infer functional states from affinity-potency data in tissue homogenates.
Antagonist-induced withdrawal is also observable after a single dose of morphine, and it subsides only gradually, long after morphine has been eliminated from the body (Martin and Eades, 1977; Heishman et al., 1990; Baldwin and Koob, 1993; June et al., 1995; Parker and Joshi, 1998 ).
Therefore, we tested whether the inverse naloxone effects on basal MOR signaling lasted for similar time periods. Indeed, after a single morphine dose, naloxone-induced inverse effects lasted for at least 24 hours ( Figure 5 ), consistent with prolonged signs of dependence and aversive naloxone effects after a single opiate exposure (last for 24 hrs) (Gianutsos et al., 1975; Heishman et al., 1990; Baldwin and Koob, 1993; June et al., 1995; Parker and Joshi, 1998) . More strikingly, after 3-day morphine pretreatment, naloxone-induced inverse effects lasted at least 72 hors ( Figure 5 ). This result indicates that while a single morphine dose is sufficient to change basal MOR signaling, multiple doses are needed to stabilize this change over a prolonged time period ( Figure 5 ). This parallels the time course of naltrexone-induced withdrawal jumping, which also lasted considerably longer after multiple doses ( Figure 7A ) than a single morphine dose (Gianutsos et al., 1975; Heishman et al., 1990; Baldwin and Koob, 1993; June et al., 1995; Parker and Joshi, 1998) . We have used here naltrexone rather than naloxone (which yield indistinguishable results in all assay) for better comparison with the chemically similar 6β-naltrexol. Parallel effects of morphine-pretreatment on basal MOR activity and withdrawal response support the view that basal signaling is intricately involved in narcotic dependence. Nalbuphine served as the internal standard. The method was sensitive to ~ 1 ng/ml (g) (3-4 nM). 6β-Naltrexol was detectable in plasma but not brain tissue after the naltrexone dose (1.9 ng/ml and 1.7 ng/ml after 10 and 60 min, respectively). In contrast, no naltrexone was detectable after administration of 6β- Naltrexone, 1 mg/kg 54 ± 16 4 ±1 69 ± 20 9 ± 1 6β-Naltrexol, 1mg/kg 61 ± 7 24 ± 28 7 ± 6 9 ± 1 6β-Naltrexol, 10 mg/kg 857 ± 122 75 ± 25 89 ± 6 74 ± 14
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